KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

Etanercept and adalimumab are both recommended to be available as routine commissioning treatment options for deficiency of adenosine deaminase type 2 (DADA2) within the criteria set out in these ...

(B) The overall design of DRAM, DRAM mut and Deaminase system. (F) Screening process for DRAM-seq assays and principles for screening high-confidence genes. (G) The pie chart shows the distribution of ...

This month's cover highlights the article Immune cells adapt to confined environments in vivo to optimise nuclear plasticity for migration by Helen Weavers and Tua Karling. The cover features confocal ...

This manuscript provides a deep mutational scanning of the deaminase domain of human ADAR2 to provide a comprehensive assessment of amino acids that alter editing activity at a specific adenosine ...